Overview

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
Insmed Incorporated